A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors
Study of Drug in Subjects with Advanced Solid Tumors
Sponsor: Astrellas Pharma Global Development
Enrolling: Male and Female Patients
IRB Number: AAAR5080
U.S. Govt. ID: NCT03260322
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for patients with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. The main purpose of the study is to determine at what dose the study drug is safe and tolerated. The study drug is called ASP8374. The study also wants to see how ASP3874 is processed in the blood. When the safe dose is identified, it will be used to learn if the study treatment causes tumors to shrink in patients. Cancers include: bladder cancer, breast cancer, colon and rectal cancer, liver cancer, lung cancer, lymphoma, skin cancer, pancreatic cancer, sarcomas, and stomach cancer.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Are you 18 years or older? Yes No
Is your tumor not able to be removed or has spread (metastasized) to a different part of the body? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator